Recently, DLK2 was described as overexpressed in lethal prostate cancers, uveal melanoma, breast cancer cell lines and in patient tissues spanning three breast cancer subtypes (Luminal A, Luminal B, and Triple Negative) [15,16,17,18]. The gene discussed is DLK2; the disease is breast cancer.